TW202613103A - 克萊拉尼的晶型及其使用方法 - Google Patents

克萊拉尼的晶型及其使用方法

Info

Publication number
TW202613103A
TW202613103A TW114142999A TW114142999A TW202613103A TW 202613103 A TW202613103 A TW 202613103A TW 114142999 A TW114142999 A TW 114142999A TW 114142999 A TW114142999 A TW 114142999A TW 202613103 A TW202613103 A TW 202613103A
Authority
TW
Taiwan
Prior art keywords
crystal form
cancer
peaks
leukemia
xrpd
Prior art date
Application number
TW114142999A
Other languages
English (en)
Chinese (zh)
Inventor
維奈 簡
Original Assignee
美商安羅格製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安羅格製藥股份有限公司 filed Critical 美商安羅格製藥股份有限公司
Publication of TW202613103A publication Critical patent/TW202613103A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW114142999A 2020-07-20 2021-07-13 克萊拉尼的晶型及其使用方法 TW202613103A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063053921P 2020-07-20 2020-07-20
US63/053,921 2020-07-20

Publications (1)

Publication Number Publication Date
TW202613103A true TW202613103A (zh) 2026-04-01

Family

ID=79291977

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114142999A TW202613103A (zh) 2020-07-20 2021-07-13 克萊拉尼的晶型及其使用方法
TW110125707A TWI905226B (zh) 2020-07-20 2021-07-13 克萊拉尼的晶型及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110125707A TWI905226B (zh) 2020-07-20 2021-07-13 克萊拉尼的晶型及其使用方法

Country Status (7)

Country Link
US (3) US11713310B2 (enExample)
EP (1) EP4181923A4 (enExample)
JP (2) JP2023536068A (enExample)
CN (1) CN113956245A (enExample)
CA (1) CA3186319A1 (enExample)
TW (2) TW202613103A (enExample)
WO (1) WO2022019998A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6960590B2 (en) 2000-10-17 2005-11-01 Merck & Co. Inc. Orally active salts with tyrosine kinase activity
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
DE60205776T2 (de) 2001-12-27 2006-06-14 Theravance Inc Indolinon-derivative als protein-kinasehemmer
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
WO2004039782A1 (ja) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
DK1641780T3 (da) 2003-06-24 2009-02-02 Pfizer Prod Inc Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
CN105294719B (zh) * 2015-11-18 2017-12-22 乳源瑶族自治县大众药品贸易有限公司 一种氨基喹唑啉类衍生物的二对甲苯磺酸盐及其晶型
KR20180074792A (ko) 2016-11-02 2018-07-03 아로그 파마슈티칼스, 인코퍼레이티드 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof

Also Published As

Publication number Publication date
WO2022019998A1 (en) 2022-01-27
US11713310B2 (en) 2023-08-01
TWI905226B (zh) 2025-11-21
US20230339918A1 (en) 2023-10-26
JP2026116949A (ja) 2026-07-14
US20220017500A1 (en) 2022-01-20
JP2023536068A (ja) 2023-08-23
US20260159506A1 (en) 2026-06-11
US12486256B2 (en) 2025-12-02
CA3186319A1 (en) 2022-01-27
EP4181923A4 (en) 2024-08-07
CN113956245A (zh) 2022-01-21
EP4181923A1 (en) 2023-05-24
TW202216696A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
CN101578283B (zh) 噻唑烷二酮化合物的晶形及其制造方法
TWI650316B (zh) Ｍｅｋ抑制劑之製備及包含ｍｅｋ抑制劑之調配物
CN101918418A (zh) 替诺福韦地索普西的固体形式
JP2011507977A (ja) （ｒ）−２−［［［３−メチル−４−（２，２，２−トリフルオロエトキシ）−２−ピリジニル］メチル］スルフィニル］−１ｈ−ベンズイミダゾールの溶媒和物結晶形
WO2024248083A1 (ja) キノリン置換化合物の結晶
JP2024045685A (ja) 結晶
TW202308991A (zh) 三苯化合物之固體形式
TWI905226B (zh) 克萊拉尼的晶型及其使用方法
TW201209041A (en) New crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
JP2024542840A (ja) Ｆｇｆｒ阻害剤の固体状形態
JP2024520141A (ja) 結晶形、それを含有する組成物、およびそれらの使用方法
WO2018188495A1 (zh) EOC315 Mod.I晶型化合物及其制备方法
TWI664172B (zh) 來那度胺的晶型及其製備方法和用途
CN105753869B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2022256550A1 (en) Crystalline forms of an adenosine a2b receptor antagonist
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
EP4631496A1 (en) Solid dispersion, preparation method therefor, and use thereof
TW201125861A (en) CDC7 inhibitor salts
US20050113410A1 (en) Pharmaceutical salts of zafirlukast
WO2026095022A1 (ja) キノリン置換化合物の結晶
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
HK40128112A (en) Polymorph as protein kinase mek inhibitor, and preparation method therefor and use thereof
CN116410133A (zh) 一种氟伐替尼氢溴酸盐及其制备方法
WO2020045475A1 (ja) ピラゾロ［３，４－ｄ］ピリミジンの結晶
AU2004272400A1 (en) Crystal of sulfonamide-containing indole compound and process for producing the same